Oral BPC-157 vs Injection: Capsules, Bioavailability and What HHS Allows

Oral BPC-157 (capsules, tablets or liquid) is sold as a needle-free alternative to injections. Under a draft HHS enforcement policy announced October 28, 2026, HHS says it does not intend to take action against 503A pharmacies that compound BPC-157 under ten conditions. The policy is not final and is not binding on HHS or the public, and comments are open until November 13, 2026^[10]. It lists oral among the allowed routes for BPC-157 acetate, alongside subcutaneous, intramuscular and topical forms, but adds a condition: a pharmacy compounding an oral form must keep documentation that the specific formulation reaches an adequate level of oral bioavailability in humans^[1]. That is the problem. No published study has measured how much oral BPC-157 a person absorbs, and a 2026 systematic review found no human study of the oral route at all^[4]. The case for capsules rests on rat studies and on BPC-157’s reported stability in stomach acid. The case for injection rests on animal pharmacokinetics. Neither route has been shown to work in people.

Oral vs injection at a glance

Sources for the table: HHS Appendix B for routes^[1]; the 2026 systematic review for human data^[4]; He and colleagues (2022) for intramuscular bioavailability^[2]; and Cerovecki and colleagues (2010) for oral and topical dosing in rats^[6].

What the draft HHS policy says about oral BPC-157

Appendix B lists BPC-157 acetate for “subcutaneous, intramuscular, oral, and topical dosage forms” compounded from bulk powder with a qualifying certificate of analysis^[1]. Condition 8 then sets the bar for oral products:

“Achieving adequate oral bioavailability of peptides is inherently difficult and complex. Therefore, if a peptide is compounded in an oral dosage form, the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans.”

— HHS 503A peptide enforcement-discretion policy, condition 8

The policy’s own testing standard leans the same way. A footnote describes the endotoxin and bioburden tests as quality attributes specific to injectable forms, “which should be the standard route of administration (ROA) for peptides due to their low oral bioavailability”^[1]. In other words, HHS allows oral BPC-157 but treats injection as the default and puts the burden of proof for oral products on the pharmacy. Because no human absorption data for oral BPC-157 have been published, ask any pharmacy offering capsules what documentation it holds for its formulation. The same condition applies to oral KPV, the other Appendix A peptide allowed by mouth.

Why oral peptides are hard to absorb

Most peptide drugs are injected because the gut is built to break proteins down. A 2020 review in Nature Reviews Drug Discovery describes the barriers to oral delivery as structural and physiological, and covers the permeation enhancers, enzyme inhibitors and other strategies drug makers use to get around them^[8]. Oral semaglutide, sold as Rybelsus for type 2 diabetes, shows the scale of the problem. It is formulated with an absorption enhancer called SNAC, and its FDA label still puts estimated absolute bioavailability at about 0.4% to 1%^[9]. Our review of oral peptides for weight loss covers this in more detail. KPV, the other Appendix A peptide allowed by mouth, faces the same oral-product condition; see KPV capsules, cream or injection.

The case made for oral BPC-157

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice, and its supporters argue it is unusually stable in the stomach. A 2024 review from the Zagreb group that has published most BPC-157 research describes it as “native and stable in human gastric juice for more than 24 h”^[7]. An independent 2026 pharmaceutical review also notes its unusual stability in gastric juice and reported activity by oral, parenteral and topical routes^[3].

The animal efficacy data support the idea that oral dosing does something in rats. In a 2010 study of a surgically cut knee ligament, BPC-157 given in drinking water improved healing over 90 days, as did daily injections into the abdominal cavity and a thin cream applied to the injury^[6]. Many other rat studies from the same group used drinking-water dosing.

Two limits apply. Stability in gastric juice is not the same as absorption into the blood; a peptide can survive the stomach and still fail to cross the intestinal wall. And the 2026 pharmaceutical review states that BPC-157 lacks permeability characterization and BCS classification data, and that no pharmaceutical-grade formulation has been developed or validated^[3]. The rat results show an effect after oral dosing in rats. They do not show how much reaches a human bloodstream from a capsule.

What about gut conditions?

For gut problems, some argue that oral BPC-157 could act locally on the gut lining without being absorbed. That is a plausible hypothesis drawn from animal models, not a tested human finding. It also does not change the policy test, which asks for documented oral bioavailability in humans for any oral compounded product^[1]. The animal and human evidence for gut uses is reviewed in our BPC-157 gut health article.

The case made for injection

The only formal pharmacokinetic study of BPC-157 tested intravenous and intramuscular dosing in rats and beagle dogs. After intramuscular injection, mean absolute bioavailability was about 14% to 19% in rats and 45% to 51% in dogs. The elimination half-life of intact BPC-157 was under 30 minutes, and the peptide was rapidly broken down into small fragments and then single amino acids^[2]. The study did not test oral dosing, and no comparable study has been published in people.

The human injection data are just as thin. The 2026 systematic review found three human studies: knee injections in 16 people, bladder instillations in 12 people, and an intravenous pilot in two people. All were of poor methodological quality, and the overall certainty of evidence was rated very low^[4]. In the intravenous pilot, two adults who had used intravenous BPC-157 before received 10 mg and then 20 mg infusions with no measured change in the heart, liver, kidney, thyroid or glucose markers tested and no reported side effects^[5]. Two people over two days cannot establish safety.

Injection also brings its own risks: an injected product has to be sterile and free of endotoxins, which is why the HHS testing standard lists those tests for injectable forms and why the only device allowed in the package is an FDA 510(k)-cleared syringe^[1]. The risks of injecting an unregulated vial are covered in our BPC-157 safety review.

The half-life puzzle

The 2026 pharmaceutical review points out a gap that affects both routes: BPC-157’s plasma half-life is under 30 minutes in animals and in a two-person human pilot, yet animal studies report effects that last hours to days. The authors call this a pharmacokinetic and pharmacodynamic disconnect with major implications for dosing and formulation^[3]. Until it is explained, nobody can say which route, dose or schedule would matter in people. Our BPC-157 dosage page explains why no evidence-based dose exists for any route, and the HHS policy sets none^[1].

Capsules sold online are not the compounded product

The draft HHS policy covers compounding by a State-licensed 503A pharmacy, Federal facility or licensed physician, on a patient-specific prescription, with a single active ingredient and the label line “This is a compounded drug product. Not for resale.”^[1] BPC-157 capsules sold to anyone online, whether labeled as a supplement or as a research product, are outside that framework, and their contents and absorption are unverified. If you are weighing a compounded oral product, ask the pharmacy for the certificate of analysis and its oral bioavailability documentation before you pay. Our BPC-157 provider page lists every seller we confirmed sells BPC-157 as a single-ingredient product, shows the form each one sells, and labels any form the policy does not cover; blends are left off. A listing does not confirm that the pharmacy meets the policy’s other conditions, so check them yourself: the certificate of analysis, a single active ingredient, the label line, an allowed route (with bioavailability documentation for capsules), a 510(k)-cleared syringe as the only device, and a State-licensed 503A pharmacy. The full set of conditions is in our HHS peptide policy explainer, and our BPC-157 guide covers the broader research.

Bottom line

Oral BPC-157 is an allowed route under the draft HHS policy, but only with human oral bioavailability data for the specific formulation, and no such data have been published^[1][4]. Rat studies show effects after drinking-water dosing^[6], and BPC-157 appears stable in gastric juice^[3], but neither shows how much a person absorbs from a capsule. Injection has animal pharmacokinetic data and a tiny, low-quality human record^[2][4]. For any route, the evidence that BPC-157 helps people is very limited.